Medtronic Secures Contract to Deploy 100 AI-Powered Endoscopy Systems for U.S. Veterans Affairs

Nov 28, 2024 17:45 CST Updated 17:46

Medtronic

Medical Device Manufacturer

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

Recently, Medtronic announced that the company has partnered with the U.S. Department of Veterans Affairs (VA).Sign an important contract to install nearly 100 artificial intelligence-driven endoscopic devices.This collaboration aims to further enhance the capabilities and efficiency of the Veterans Medical Center in colorectal cancer screening, marking another significant milestone in the field of medical technology for both parties.

According to reports,This three-year contract expands Medtronic's long-term partnership with the VA, adding GI Genius colonoscopy modules across VA medical centers nationwide.

Data shows that Medtronic's GI Genius, as an advanced artificial intelligence-assisted system, can analyze images in real time during colonoscopy, accurately detect potential polyps, and effectively assist doctors in making more precise diagnoses.In 2021, the U.S. FDAOfficially authorized GI Genius for clinical use.

Medtronic willFor VA Medical Center

Add GI Genius Colonoscopy Module

It is understood that Medtronic rigorously trained and validated the GI Genius using a large amount of histologically confirmed polyp video data, and successfully demonstrated the significant advantage of this technology in improving adenoma detection rates in a randomized trial in 2020.

Since 2022, the VA has gradually introduced Medtronic's GI Genius device,The initial installation quantity reached 115 sets.With the signing of this new contract,Medtronic stated that its collaboration with the VA will cover more than 360 GI Genius devices.Installation has been completed at more than 140 VA medical facilities across the United States and Puerto Rico, demonstrating the firm commitment of both parties to improving the quality of healthcare services for veterans.

The VA performs approximately 250,000 colonoscopy procedures annually, playing a crucial role in the colorectal screening efforts across the United States, with about 4,000 cases of colon cancer diagnosed each year. Traditional colonoscopy methods carry a certain risk of missed diagnosis, and research has shown that increasing the adenoma detection rate can significantly reduce the incidence and mortality of colorectal cancer. Randomized trial data from Medtronic indicates,The adenoma detection rate of GI Genius is as high as 54.8%, showing a significant advantage over the control group's 40.4%, providing strong technical support for early cancer screening.

The advancement of this artificial intelligence endoscopy project not only demonstrates Medtronic's leading position in the field of medical technology innovation but also reflects the VA's active acceptance and application of advanced medical technologies. Medtronic stated that this collaboration is part of its broader strategic layout in the AI healthcare sector.Last week, the company also announced another research advancement, utilizing Tempus's Next platform to screen patients suitable for advanced interventional treatments such as transcatheter aortic valve replacement, showcasing its diversified exploration and deep cultivation in the field of intelligent healthcare.

As artificial intelligence technology continues to penetrate the healthcare industry, the collaboration between Medtronic and VA will set a new benchmark for future cancer screening and precision medicine. This partnership is expected to enhance patient diagnosis and treatment experiences and outcomes on a larger scale, driving the entire healthcare industry towards intelligent and precise directions.

GI Genius is

GlobalThe First Approved Colonoscope

As the world's first colonoscope to receive FDA approval, the birth of GI Genius is revolutionary.Its main function is to assist doctors in detecting polyps that may be present during colonoscopy, including polyps as small as a few millimeters, through deep learning algorithms and image analysis.This can effectively reduce the risk of colorectal cancer.

The clinical data at that time showed,GI Genius detects 82% faster than doctors, with an error rate of less than 1%. Its adenoma detection rate is 14% higher than that of conventional colonoscopy, and the likelihood of detecting polyps is increased by 30%.Moreover, this module is compatible with all FDA-approved endoscopic video systems, such as Olympus, Fujifilm, and Pentax.

GI Genius Module as an Artificial Intelligence Software Application for Detecting Precancerous Polyps, the SystemIntegrated with the AI Access platform, it is expected to host multiple artificial intelligence software applications.This is an open and scalable platform jointly developed by Medtronic and IMD at an early stage, aimed at hosting, managing, and supporting multiple AI diagnostic tools from third-party developers.

In other words,Third-party developers can obtain login access through the AI Access platform, enter the Innovation Center, utilize its tools and resources, and create customized healthcare applications according to their own needs and goals.Moreover, once third-party developers successfully create new artificial intelligence applications and receive approval from market regulators, these programs can be integrated into the GI Genius module via the AI Access platform.

Launch the latest version

Colonoscopy AI System

Data shows that in 2021, Medtronic's GI Genius intelligent endoscopy module received FDA approval in the United States, becoming the first and only AI system for colonoscopy.

In 2024, Medtronic and the Cosmo team launched the latest version of the colonoscopy AI system — the GI Genius™ platform.Improved polyp detection features, including new functions such as automatic program highlighting, and opened the GI Genius operating system to third-party software developers.This GI Genius™ platform, integrated with the latest NVIDIA IGX™ platform, has entered the final stage of regulatory approval and is expected to be launched in the third quarter of this year.

GI Genius™ was conceived, designed, developed, and manufactured by Cosmo IMD and is distributed globally by Medtronic.

According to the expanded agreement terms, Medtronic plans to pay Cosom an advance of 100 million US dollars. The agreement also includes a double-digit net sales royalty that is in line with market standards.Medtronic is required to pay an additional $100 million in potential milestone fees, which are expected to be achieved by the end of 2024. Cosmo remains the exclusive manufacturer, granting Medtronic exclusive global commercial rights.

It is reported that Cosmo is a pharmaceutical company focused on the development and commercialization of treatments for specific gastrointestinal diseases, improving quality indicators for endoscopic procedures through the auxiliary detection of colon lesions, as well as treating specific dermatological conditions. The products developed and manufactured by Cosmo are globally distributed by selected partners, including Lialda®/Mezavant®/Mesavancol®, Uceris®/Cortiment®, Aemcolo®/Relafalk®, Lumeblue®, and Winlevi®.

The Competition in the Medical AI Endoscopy Market is Fierce

As the gold standard for colon cancer screening, endoscopy has high sensitivity and accuracy. However, missed diagnoses often occur due to factors such as the structure of the colon and variations in lesions.

The length of the colon in normal adults is about 1.5 meters, and there are significant individual differences in its morphology within the abdominal cavity. The bends and folds inside the colon can lead to blind spots in the field of view. Not only that, but many colonic lesions appear deceptive in images, resembling normal mucosa very closely, which poses a great challenge to the skill level of the examining physician.

Colon cancer is the third leading cause of cancer death in the United States.Data from 2020 shows that there were 555,000 new cases of colorectal cancer in China, making it the second most common cancer, accounting for approximately half of the global new cases of colorectal cancer.

As a result, colon cancer/gastrointestinal endoscopy-assisted diagnosis has become a battleground crowded with medical AI. In the current field of medical artificial intelligence imaging, AI-assisted diagnosis for gastrointestinal endoscopy is alsoThe first artificial intelligence diagnostic project to be included in clinical guidelines in China.

As early as 2017, Japan's National Cancer Center and NEC Corporation announced the development of an artificial intelligence system for the automatic diagnosis of polyps in colonoscopy., trained on 140,000 colonoscopy images and tested on 5,000 colonoscopy images, achieving an accuracy rate as high as 98%.

Notably, several AI-assisted endoscopy innovative products from companies such as Tencent Healthcare, Chengdu Visionsense Medical, Wuhan Chuling Technology, Suzhou Huiwei Intelligence, and Zhejiang Huirui Medical have been approved in China.

——

Currently, a large number of studies and practices clearly indicate that conducting colorectal cancer screening and implementing early diagnosis and treatment can significantly reduce the incidence and mortality of colorectal cancer.Early screening for colorectal cancer not only has a strong market demand but also targets a large population, giving rise to a substantial market volume.

Medtronic is precisely targeting this huge market,Including this timeNearly 100 sets of AI endoscopy equipment installed,Medtronic and VA Collaboration Covers Over 360 GI Genius Devices。AndIn recent years, the growing customer installation base of GI Genius indicates a promising market capacity in the future. In response, Device China will continue to follow and report on the development.

END

Industry Giant Announces Restructuring, Stock Price Soars 29%

Backed by 110 million people, Beijing to Introduce World-Class International Hospitals

Minimally Invasive, Neusoft Bet: The Only Surgical Robot in the Industry Approved in China

Boston Scientific, Second Acquisition This Month

World's First Self-Shielding Radiotherapy Robot to Be Mass-Produced in China

China-produced New Generation 7T MRI Wins 85.6 Million RMB Bid at Qilu Hospital of Shandong University

Philips, Hand in Hand with "World's First"

CGM Leader Enters the $362 Million "Ring" Market

Next week, the world's largest medical imaging conference is coming.

Siemens Healthineers + Dental Leader: The World's First Dental MRI is Here

BusinessBusiness cooperation email: qxzj@landianyiliao.com